Arena Pharmaceuticals (ARNA) 10-Q2017 Q1 Quarterly report

Filed: 9 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: absence, Agent, allotted, ATM, average, bid, Biliary, brain, Brokerage, bulletin, Citigroup, clarify, closing, confirmed, consecutive, Craig, customer, deducting, deliverable, depict, Derm, Dermatological, destruction, deter, domain, Fetzer, forward, Gangrenosum, Garry, hostile, IBD, inclusive, IP, Jayson, Klassen, led, Leerink, LLC, mechanism, mix, Neil, odd, Oliver, opposition, optimized, ordinary, OTC, passed, pathway, PBC, peripherally, PG, physically, pill, Pink, poison, possession, precursor, premium, Preston, principle, prompted, put, Pyoderma, quotation, regain, repeal, rest, selexipag, split, sublicense, threat, underwriter, underwriting, underwritten, unlisted, unrelated, USA

Removed: achieved, achieving, Amit, area, assessment, authorization, award, awarding, banding, borne, calculated, calendar, CAMELLIA, cancer, carcinogenicity, card, category, charge, chemistry, CHMP, chronic, coincide, collaborative, committed, conclusive, constitute, content, continuation, couple, coupon, creation, criterion, CRL, demonstrating, deny, derivative, diet, discount, discounted, doubt, dropout, effected, EMA, equaled, exceeded, exported, feedback, final, finalized, financially, forfeiture, formatting, fourth, free, gastric, half, Harry, herbal, Hixson, impede, impeded, imported, imposition, impossible, Improving, IND, initiation, institution, inventor, investing, invoiced, joined, Jr, justify, kind, language, lengthy, letter, logo, MAA, Medicinal, Mexico, misuse, Munshi, noncompliance, Nordisk, Novo, obligated, opposed, opt, Orexigen, original, partial, PDUFA, planned, positively, practice, preclude, predicting, Presentation, psychiatric, recently, recommended, record, refund, refusal, regularly, requested, requisite, rescheduled, reserve, reset, resolve, revaluation, satisfactory, screening, selected, separation, served, setback, simplify, space, stringent, submission, sufficiently, supplying, supported, surgery, surgical, tablet, threatened, tightly, timeframe, toxic, toxicity, Transparency, unacceptably, understood, user, utilization, utilized, vast, voucher, warrant, withdrew

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ARNA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Arena Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Amit Munshi, as President and Chief Executive Officer of the Company, and Kevin R. Lind, as Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1.	the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Amit Munshi			/s/ Kevin R. Lind
Amit Munshi			Kevin R. Lind
President and Chief Executive Officer			Executive Vice President and Chief Financial Officer

Date: May 9, 2017			Date: May 9, 2017

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.